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Abstract
Renal cell therapy employing cells derived from adult renal epithelial cell (REC) progenitors promises
to reduce the morbidity of patients with renal insufficiency due to acute renal failure and end stage
renal disease. To this end, tissue engineered devices addressing the neglected biologic component of
renal replacement therapy are being developed. Because human donor tissue is limited, novel enhanced
progenitor cell propagation (EP) techniques have been developed and applied to adult human kidney
transplant discards from six donors. Changes include more efficient digestion and the amplification of
progenitors prior to terminal epithelial differentiation promoted by contact inhibition and the addition
of retinoic acid. Differentiated morphology in EP populations was demonstrated by the ability to form
polarized epitheliumwith tight junctions, apical central cilia and expression of brush border membrane
enzymes. Evaluation of lipopolysaccharide stimulated interleukin-8 secretion and g–glutamyl transpep-
tisade activity in EP derived cells was used to confirm therapeutic equivalence to REC obtained using
published techniques, which have previously shown efficacy in large animal models and clinical trials.
Yield exceeded 1016 cells/gram cortex from the only kidney obtained due to an anatomical defect, while
the average yield from diseased kidneys ranged from 1.1109 to 8.81011 cells/gram cortex, represent-
ing an increase ofmore than 10 doublings over standardmethods. Application of the EP protocol to REC
expansion has solved the problem of cell sourcing as the limiting factor to themanufacture of cell based
therapies targeting renal diseases and may provide a method for autologous device fabrication from
core kidney biopsies. Copyright © 2012 John Wiley & Sons, Ltd.
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Keywords kidney; adult stem cells; tissue expansion; tissue engineering; renal insufficiency
1. Introduction
Acute renal failure (ARF) and chronic renal disease (CRD)
are distinctly different disease processes and current
therapy for both disorders is suboptimal. ARF arises from
toxic or ischaemic (usually simultaneous) tubule damage
from antibiotics, chemotherapeutic agents or shock
during infectious or major operative procedures. The
development of ARF in a hospitalized patient results in a
five- to eight-fold higher risk of death (Humes, 1995;
Chertow et al., 1998; Bates et al., 2001), with overall
mortality rates exceeding 50%. However, if the patient
survives the episode of ARF, the regenerative repair
processes within the kidney can result in a return of
kidney function in 90–95% of patients with this acute
disorder. The cause of death in patients with acute renal
failure is usually the development of Systemic Inflammatory
Response Syndrome (SIRS), with resulting cardiovascular
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collapse, ischaemic damage to vital organs and multiple
organ failure (MOF) (Humes, 2000; Humes et al., 2002).
The propensity of patients with ARF to develop SIRS and
sepsis suggests that renalmetabolic function, specifically renal
tubule cell function secondary to Acute Tubular Necrosis
(ATN), plays a critical immunomodulatory role in individuals
under stress states. This function is not replacedwith standard
dialysis therapy.
Unlike ARF, CRD is an irreversible process of progres-
sive kidney damage, commonly from diabetes and
hypertension, which leads to end-stage renal disease
(ESRD). Patients with ESRD on dialysis continue to have
major medical, social and economic problems with life
expectancies of only 4–5 years (Iglehart, 1993; Xue et al.,
2001; Cukor et al., 2007). While the ideal standard for
kidney replacement therapy for ESRD remains organ
transplant, with less than ten thousand kidney transplants
completed each year and the current number of patients
awaiting transplantation approaching sixty thousand
(Collins et al., 2005), the need far exceeds availability.
For all disease processes, available renal replacement
therapies consisting of haemofiltration, haemodialysis or
chronic ambulatory peritoneal dialysis are non-physiolog-
ical and fail to address the homeostatic, regulatory, meta-
bolic and endocrine functions of the kidney. Patients with
ESRD are at high risk for cardiovascular and infectious
diseases, despite conventional renal replacement
therapy. A recent clinical trial failed to show survival
benefit from increased doses of dialysis above the current
standard of care (Humes, 1995), suggesting that there are
important metabolic derangements not adequately
treated with conventional dialytic treatment. Survival of
renal transplant recipients far exceeds that of age-, sex-
and risk-matched controls awaiting transplant, clearly
demonstrative of the metabolic function provided by
the kidney beyond filtration. ESRD currently affects over
430 000 US patients and has an annual cost of more than
$25 billion, and patient numbers are predicted to increase
to 2.24 million by 2030 (Schrier and Wang, 2004).
The potential success of renal cell therapy lies in the grow-
ing appreciation that most disease processes are not due to
the lack of a single protein, but develop due to alterations
in complex interactions of a variety of cell products. The renal
tubule cell’s roles in glutathione reclamation, glutathione
peroxidase synthesis and activation of vitamin D3, with its
important immunoregulatory functions, are well-recognized
pathways to maintain important tissue integrity and host de-
fence under stress conditions (Humes, 2000; Humes et al.,
2002). A less recognized role of the kidney, chiefly the renal
tubule, is its potential immunoregulatory function. The kid-
ney is derived embryologically from dorsal mesoderm, a
collection of cells also important in the development of
bone marrow stem cells (Turpen and Knudson, 1982;
Saxen, 1987). The maturation of cells responsible for
erythropoietin synthesis and activation of 1,25-(OH)2
vitamin D3 in the kidney is reflective of this embryonic
origin. Phylogenetically, in bony fish and amphibians
without lymph systems, the kidney is the major antibody-
producing organ (Smith et al., 1967; Zapata, 1979; Turpen
and Knudson, 1982). Not surprisingly, mammalian renal
proximal tubule cells are immunologically active. They are
antigen-presenting cells (Bishop et al., 1988; Wuthrich
et al., 1990) that possess co-stimulatory molecules (Wahl
et al., 2002) and that synthesize and process a variety
of inflammatory cytokines (Prodjosudjadi et al., 1995;
Leonard et al., 1999; van Kooten et al., 1999).
The development of renal epithelial cell (REC) therapy
to replace the endocrine and immunological functions of
the kidney, in addition to haemofiltration, promises to
add significant value to the current suboptimal treatments
of renal failure. Candidate biological markers that are
known to be dysregulated in ESRD correlate with poor
outcome and are linked to known mechanisms of disease,
include markers of inflammation and oxidative stress.
A methodology to isolate and grow REC from adult
human kidneys has already been developed (Smith
et al., 2006) and the described methods used to provide
the renal cell component of tissue-engineered devices
evaluated in large animal and clinical studies (Tumlin
et al., 2008). However, using standard cell-processing
techniques, RECs isolated from human transplant discards
do not have the expansion capability required to provide
cell therapy for the large patient population suffering
from ARF and ESRD. The ability to differentiate a
totipotent embryonic stem cell down an intricately
orchestrated kidney-specific path is still in its infancy
and does not provide a timely solution to cell sourcing
for renal replacement therapy. Clinical and experimental
observations suggest that REC progenitor cells have
immense proliferative potential, as evidenced by complete
Table 1. Comparison of standard vs. enhanced propagation protocols
Step Standard method Enhanced propagation
Enzymatic digestion Collagenase<600mM particle size Liberase/Blendzyme. Single cell!212mM particle size
Centrifugation 50g (exclusive) 300g (inclusive)
Plating density 500ml pellet/100mm plate 4–32 ml pellet/100mm plate
Media change 24h post-plating, non-adherent cells
removed by aspiration
7days post-plating, non-adherent cells retained
Matrix Collagen IV/adsorbed FCS Endogenous matrix
Subculture ~1107 cells seeded and 2107
recovered per T75 flask. Pass ratio 1:2
1.25106 cells plated and 2107 cells recovered
per T75 flask. Pass ratio ~1:16
Differentiation factor retinoic acid Added prior to primary passage. Cells
remain differentiated through passages
Signals the end of precursor amplification. Added
on device or test well after confluence (contact
inhibition)
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tubule regeneration to reform a fully functional and
differentiated epithelium after severe nephrotoxic or
ischaemic injury (Duffield and Bonventre, 2005). This
regeneration potential has been attributed to haematopoetic
or mesenchymal stem cells, rather than resident
renal progenitor cells, with controversial results (Poulsom
et al., 2001; Gupta et al., 2002; Kale et al., 2003). The most
pertinent observation from these studies was that
injection of mesenchymal stem cells following ischaemic in-
jury enhances the regenerative potential and recovery of
tubules, occurring without actual incorporation of
these cells into the regenerated tubules, possibly due to a
paracrine effect (Bi et al., 2007; Imai and Iwatani, 2007).
Current opinion is that precursors responsible for
the repopulation of tubules reside within the kidney,
possibly maintained within a specialized niche (Al-Awqati
and Oliver, 2006; Sagrinati et al., 2006), although the
defining characteristics and mechanism are still under
investigation (Duffield and Bonventre, 2005; Al-Awqati and
Oliver, 2006; Challen et al., 2006). Regardless of source, these
resident kidney progenitor cells have stem cell-like character-
istics, with a high capacity for self-renewal and the ability to
differentiate under defined conditions into mature somatic
cells, as evidenced by tubule regeneration (Hall and Watt,
1989; Potten and Loeffler,1990). An approach tomore closely
mimic the in vivo environment promises to greatly enhance
REC propagation potential and is the basis of these studies.
2. Materials and methods
2.1. Tissue procurement
Human cadaver kidneys, rejected for organ transplanta-
tion due to anatomical or fibrotic defects, were procured
from the National Disease Research Interchange (NDRI). Ad-
ditional donor acceptance criteria included: adults< 80years
of age, blood tests negative for adventitious viruses, non-
septic, normal creatinine and blood urea nitrogen levels, no
other indices of kidney disease, and time between cross-clamp
and the beginning of tissue processing≤36h. Tissue from six
donorswas simultaneously processed using enhanced prop-
agation (EP) and the standard protocol. The method
modifications are highlighted in Table 1.
2.2. Cell isolation
Kidneys were dissected clean of all external tissue, the
capsule removed, the cortex cut from the medulla and the
cortex weight documented. Finely minced cortex was
digested at 1 g tissue/ml prewarmed enzyme (collagenase
for the standard protocol or Liberase for EP)/DNase (0.239
Wunchst units and 250 Kunitz units/ml) at 37 C for 20min
cycles. Using the standard protocol, the digestion was
quenched with cold Dulbecco’s modified Eagle’s medium
(DMEM) and all tissue aggregates> 850mmwere returned
to the digestion flask and the cycles repeated. The
quenched slurry was subsequently sieved without further
enzymatic digestion and remaining tissue aggregates> 600
mm were discarded. For EP, the enzymatic digestion
proceeded uninterrupted with only the< 212mm sieved
filtrate being quenched as it passed into the collection
beaker containing cold DMEM. To evaluate the relationship
of aggregate and cell yield, EP slurry was further fraction-
ated by differential sieving into 150–212, 90–150, 38–90
and< 38mm fractions. For the standard method, the tissue
was washed by centrifugation at 50 g to preferentially retain
intact tubules, while EP tissue was centrifuged at 300 g,
which was inclusive of single cells and aggregates that may
have contained damaged and therefore more buoyant tubules.
2.3. Primary plating
RECs were cultured in UltraMDCK medium (UM, Lonza)
supplemented with half the manufacturer’s recommended
dilution for insulin, transferrin, ethanolamine and selenium
supplement (ITES; Lonza), 60ng/l epidermal growth factor
(hrEGF; R&D Systems), 10–9M triiodothyronine and 1
penicillin–streptomycin. Standard plating density was 1ml
50 g pellet/24ml medium (20ml/T75 flask), and the
non-adherent fraction was aspirated as a result of the first
medium change after 24h in culture. For EP plating, the
cells were further diluted 1:16 by suspending 1ml of the
300 g pellet/384mlmedium (20ml/T75 flask). For three
donors, initial plating density was evaluated over a wide
range by continued 1:2 dilution until 1:516 dilution was
achieved. Partial medium changes (50%) were performed
on an as-needed basis, with need assessed by monitoring
glucose (Stanbio), lactate (Van Den Hamer and Elias,
1958; Krieg et al., 1967) and pH of the culture medium.
Non-adherent cells were retained from primary EP culture
through the first passage.
For both methods, subculture was accomplished as
follows: cells were rinsed free of divalent cations,
enzymatically released from plates using 0.05% trypsin–
versene (Lonza) by incubation for 20min at room temper-
ature, and the reaction inhibited by 0.1% w/v soybean
trypsin inhibitor (Gibco). Upon reaching tight confluence,
retinoic acid (RA) was added to standard cultures 24 h
before the first passage and cultures passed at 1:2, thus
maintaining confluency in the range 50–100%. Enhanced
propagation cultures did not receive RA at confluence and
were subcultured at 105 cells/ml, 12ml/100mm plate,
and passaged when 50–75% confluent, maintaining con-
fluency in the range 6.25–75%. For both standard and
EP cultures, RA was added to the medium just prior to
use, at a concentration of 10–7M.
2.4. Assessment of identity and function
Tests were made on increasingly passaged EP cultures,
while those generated using standard protocols were tested
at the fifth passage, the point at which standard populations
were integrated into devices for clinical studies. For all tests,
EP cells were seeded at confluent density, 106 cells/ml/
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5 cm2. RA was added after 2 days and the cells cultured for
an additional 5 days prior to testing. For cytokine
evaluation, the cell medium was supplemented with 0.1%
bovine serum albumin, both with and without 10mg/ml
lipopolysaccharide (LPS); the supernatants were removed
at 24h, clarified by centrifugation and the concentration
of IL-8 determined by ELISA (R&D Systems). A quantitative
g-glutamyl transpepsidase (gGT) enzyme assay was devel-
oped using g-glutamy-p-nitoanalide, a commercially avail-
able, gGT-specific colorometrc substrate (Stanbio) (Szasz,
1974). Activity was assayed in whole cell lysates prepared
using a non-ionic detergent buffer and normalized with
protein concentration (BioRad). One unit of activity is
defined as the conversion of 1mM reagent/min/mg protein
at 37 C. For immunohistochemistry (IHC), cells were fixed
in 4% paraformaldehyde, permeated with 0.1% Triton
X-100 and subsequently labelled with antibodies to REC-
specific markers, including acetylated tubulin (AT1;
Zymed), zona occludens-1 (ZO1; Zymed), gGT (Lab Vision)
and aminopeptidase-N (APN; Becton Dickinson), and the
nuclei labelled with 4’,6-diamidino-2-phenylindole dihy-
drochloride (DAPI).
2.5. Cryopreservation
Trypsinized cells were mixed at 107 cells/ml in cryopro-
tectant medium (10% DMSO in UM), placed in a con-
trolled-rate freezing apparatus (Nalgene, Mr. Frosty) at
80 C overnight and then transferred to the vapour
phase of liquid nitrogen. The cells remained frozen for
at least 2weeks prior to use in cryopreservation studies.
Figure 1. Cell yield calculations. Application of the enhanced propagation (EP) protocol for the isolation and propagation of renal
epithelial progenitor cells to human cadaver kidneys greatly increased yield. (a) Yield increase is observed at the first passage.
Progenitor cells are present in all sieved cell fractions, shown by fraction (red) far right, including the<38mm portion, in which
any 3D stem cell niche would be destroyed. Representative results from the 13 September 2008 isolate are shown. (B) Cell yield/g
cortex was proportional to dilution factor at primary plating. The results shown are averageSE for n=3 isolates. (C) The growth
curves of six individual EP isolates and the average standard are plotted as total cell number through time. Although growth potential
varies greatly between isolates, the plots clearly demonstrate that a far greater cell mass was obtainable using EP techniques; note the
logarithmic scale displayed on the vertical axis (cell yield/g cortex). In (A, B) primary yield is defined as the number of cells resulting
from the initial plating, counted post-trypsinization prior to subculture
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The cells were allowed to recover by plating and passaging
using the EP propagation protocol before seeding at conflu-
ent density for characterization.
3. Results and discussion
Independent culture of sieved fractions confirmed that
all aggregate pools contributed significantly to the EP
precursor pool. A representative plot of the yield from
the primary plating of each sieved portion is shown
in Figure 1A. The proliferation potential of the< 38mm
portion, in which any three-dimensional (3D) stem cell
niche would be destroyed, was essentially equivalent to
the 38–90mm portion and persisted through continued
passaging. Plating density was investigated in four of
six isolates and representative results are shown in
Figure 1B. Yield/g cortex increased inversely to plating
density at primary passage. However, cultures plated at
dilutions> 1:16 of the standard protocol were subject
to an island effect, in which cells become contact inhib-
ited at the centres of islands. For continued expansion,
these dilute cultures required passage before the tissue cul-
ture medium became depleted. Cells plated at 1.25106
cells/20ml/75 cm2 flask (a concentration calculated from
1:16 of a confluent 75 cm2 flask =2107 cells) required
weekly passage, essentially eliminating the need for me-
dium changes between passage days and dramatically de-
creasing the reagents, supplies, effort and therefore cost of
maintenance over more dilute cultures. For the remainder
of this report, all assays for identification and efficacy focus
on EP cells plated at 1:16 and subcultured at 1.25106
cells/20ml/75 cm2 flask.
In Figure 1C, growth curves of REC progenitors from
each donor are plotted as cell yield/g cortex through cul-
ture time, along with the average yield from the standard
method for comparison. All EP cultures maintained expo-
nential growth for at least 6weeks, with the exception of
the 9 May 2009 isolate, the only one that was terminated
due to senescence. The others were terminated because
they did not form epithelial monolayers when plated at
higher density on tissue culture surfaces. Instead, they
had a greater affinity for each other and aggregated into
3D structures in suspension. Yield exceeded 1016 cells/g
cortex from the only kidney obtained due to an anatomical
defect, while the average yield from diseased kidneys was
in the range 1.1109–8.81011 cells/g cortex, represent-
ing an increase of 10.31.4 doublings over standard meth-
ods. Because the cell numbers obtained using the EP meth-
ods were sufficient by the time the effect was observed,
further propagation and analysis of these cells was not pur-
sued. The plots clearly demonstrate the far greater cell mass
obtainable with EP techniques; note the logarithmic scale
displayed on the vertical axis (cell yield/g cortex). The cell
yields for both methods and relevant donor information are
provided in Table 2.
During primary propagation at low density, REC pro-
genitor cells are highly motile, forming adherent islands,
floating rafts and non-adherent spheroids (Figure 2A–C).
Using standard methods, part of the progenitor pool is
discarded as a result of the initial medium change and
the non-adherent structures do not have time to form.
As cell density increases, the cells coalesce into islands
with cuboidal centres and spindle-shaped cells at the
outer edges (see Supporting information, Video S1).
When plated at higher density with RA for functional test-
ing, the cells quickly develop the familiar cobblestone ap-
pearance associated with REC, with occasional doming
(Figure 2D, E; see also Supporting information, Video
S2). As shown in Figure 3A, advanced EP cultures
retained the ability to form polarized epithelium, as
evidenced by the formation of apical central cilia,
revealed by punctuate AT1 labelling, and the distinctive
spider-web pattern of tight junctions was demonstrated
with ZO1. The brush border enzymes APN and gGT per-
sisted in advanced EP cultures (Figure 3B, C). The results
from the gGT enzyme assay complemented IHC results,
with 160 43 and 242 37 U/mg protein for the stan-
dard and EP cells, respectively. No trend was observed
as the cultures aged; however, for both populations there
was a significant decrease in gGTenzyme activity detected
in cells post-cryopreservation, dropping to 7814 and
99 23 U/mg protein for the standard and EP cells,
respectively (Figure 4A).
Table 2. Relevant donor history and yield
Isolation date












13 February 2008 6.3107 9.21010 3.0108 10.4/5.6 Anoxia 57 F D, HT, T, EtOH, A 6%
21 March 2008 1.3107 3.71010 2.71010 11.5/11.0 Trauma 50M HT 4%
13 May 2008 2.6107 9.21016 6.31012 31.7/17.9 CVAb 65M 0%
13 September 2008 4.3107 8.81011 2.21010 14.3/9.0 Anoxia 51 F HT, T, EtOH Biopsy not
performed
30 October 2008 5.3107 3.21010 6.61010 9.2/10.3 CVA 52 F D, HT, T, EtOH, A 14%
9 May 2009 2.0107 1.1109 Not determined 5.8/ND CVA 78M D, HT, T, RS 20%
Cell mass generated from enhanced propagation (EP) methods is diminished by cryopreservation (CRYO), but still far exceeds that of the
standard protocol. Yield is highly dependent on prior disease state of donor and ranges from>1016 cells/g cortex derived from a relatively
healthy donor to<1010 from a kidney known to be diseased. At a projected cell therapy dose of 108 cells, the 13 May 2008 donor would
yield over 108 devices from a single g of cortex.
aD, diabetes; HT, hypertension; T, tobacco use; EtOH, alcohol use; A, asthma; RS, renal stent.
bCVA, cardiovascular accident.
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EP-generated REC retained the ability to respond
to endotoxin challenge through advanced culture. LPS
stimulated IL8 secretion for all populations tested; how-
ever, the amount of IL8 released was highly variable
across donors for the standard populations, averaging
6.3 3.4 and 17.6 8.6 ng/106 cells/24 h for basal and
stimulated, respectively. EP rates were more consistent
between donors, with the average being 3.41.1 and
19.73.5 ng/106 cells/24 h for basal and stimulated,
and remained within the secretion ranges detected for
the standard cultures. The ability to respond to endotoxin
challenge persisted through cryopreservation, with basal
and stimulated rates being 6.3 3.4 and 19.19.6ng/106
cells/24h for standard and 5.0 2.1 and 18.74.2ng/106
cells/24 h for basal and stimulated EP populations
(Figure 4B).
Cryopreservation had a detrimental effect on prolifera-
tion potential. In addition to a low initial recovery rate of
80% (8106 viable cells from each vial containing 107
cells upon cryopreservation), the overall growth potential
was greatly diminished. For the two isolates with the low-
est potential, growth rates were unaffected. However, for
the isolates having the greatest proliferation potential
prior to cryopreservation (13 February 2008, 13 May
2008 and 13 September 2008), the growth potential
was reduced between two and four orders of magnitude
(Table 2).
Application of EP protocols to human kidneys has sig-
nificantly increased cell yields compared to the standard
method. In aggressively digested kidney cortex, the< 38
mm fraction, which consists of mostly single cells, still
retained a high potential for proliferation, indicating that
the retention of a 3D stem cell niche is not a requirement
for transient amplification of renal progenitors. Yield
was inversely proportional to plating density, while
partial medium changes increased yields, indications
that more than one factor may be influencing REC
progenitor propagation.
Unfortunately, the available kidney pool for REC ther-
apy consists of donors having pre-existing serious health
Figure 2. Morphology of REC propagated using the EP protocol. In primary culture REC progenitors form non-adherent floating rafts
(A) and hollow spheroids (B), as well as adherent spindle-shaped cells. Post-cryopreservation, progenitor cells kept at low density re-
main in the exponential growth phase, retaining the spindle-shaped morphology (C). When plated at density with RA, previously
cryopreserved cells acquire the cobblestone morphology of differentiated RECs (D), with occasional doming (E). Standard culture
at passage 5 is shown for comparison (F)
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issues, including diabetes, hypertension and sclerosis of
the kidney. Although donor health had a large impact
on progenitor cell amplification, the post-cryopreservation
cell yields from suboptimal donors exceeded 1010 cells/g
cortex while retaining the appropriate morphology
and ability to express surrogate efficacy markers. With a
Figure 4. Retention of therapeutic potential through cryopreservation. (A) g-Glutamyl transpepsidase (gGT) enzyme activity was
detected in renal epithelial cells generated from both standard (STD) and EP cultures but was greatly diminished post-cryopreservation
(CRYO). (B) Addition of lipopolysaccharide (LPS) stimulated IL8 secretion over basal secretion level in all cultures tested and was not
affected by cryopreservation. Average resultsSE for n=4 donors are shown
Figure 3. Immunohistochemical comparison of REC propagated using the EP protocol (A–C) compared to the standard protocol
(D–F). EP-generated RECs form polarized epthelial monolayers, as demonstrated by acetylated tubulin-positive apical central cilia
(red), while zona occludens (green) is concentrated in tight junctions having a distinct spider-web pattern (A, D). Expression of the
renal brush border enzymes aminopepsidase N (B, E; red) and gGT (C, F; red) persists. DAPI counterstaining is shown in (B, E, C;
blue).The photographs are representative of advanced EP cultures at yields>100 times that possible with the standard protocol,
compared to passage 5 standard cultures (= passage historically used for therapy). Scale bar=100mm
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cell load/device expected to be 108 cells, and cortex
weight of about 50 g/kidney, this correlates to more
than 5000 devices from a single donor kidney, a vast
improvement to the 1–10 devices demonstrated using
standard methods. The only kidney donor with no
known disease (13 May 2008) yielded over 1016 cells/g
cortex.
With amplification of renal progenitor cells to this
magnitude, the EP protocol could be successfully ap-
plied to tissue obtained from a kidney biopsy for
autologous device manufacture for chronic applica-
tions. Kidney biopsies are routinely taken for diagnostic
purposes and range from a few milligrams for a needle
biopsy to around to 50mg for a wedge biopsy. If the
method was applied successfully to the non-diseased
13 May 2008 isolate, 6.31012 cells, or approximately
sixty three thousand autologous devices, could theoret-
ically be manufactured from a 50mg wedge biopsy. For
proof of principle, the EP method was applied to an
11mg simulated needle biopsy taken from the whole
donor kidney prior to dissection on 9 April 2009. Even
though the simulated biopsy was from the kidney of
the oldest donor with the most pre-existing health
issues, and had the lowest overall yield, application of
the EP method still yielded enough cells (> 108) for
one autologous renal cell therapy device (data not
shown).
To compare cells from standard methods and those
generated using the EP protocol, surrogate markers were
evaluated in addition to establishing equivalent morphol-
ogy. LPS-stimulated IL8 secretion and gGTenzyme activity
were chosen because they correlate with the ability to
respond to inflammation and oxidative stress, mechan-
isms that are known to be dysregulated in ESRD and
correlate with poor outcomes. Additionally, basal IL8
secretion was used as a release criterion for previous
clinical trials involving REC (Tumlin et al., 2008).
Because the immunoregulatory role of the kidney is
very complex and response is highly individualized to
the animal or patient (Humes et al., 2003), the useful-
ness of a surrogate marker panel in relation to actual
therapeutic benefit remains unclear. Nevertheless, corre-
lation of in vitro measurements to efficacy will be
required for the transition of REC therapy to the clinical
setting, and therefore the pursuit of surrogate markers
remains a topic of emphasis. Because gGT enzyme
activity and the ability to respond to endotoxin chal-
lenge in expanded EP cultures are retained through
cryopreservation, these functions provide very promising
efficacy markers. EP-derived cells in a bioartificial renal
cell system are currently being evaluated using a por-
cine model of sepsis, where cells are in contact with
the ultrafiltate in a haemodialysis circuit. In this
model, renal cell therapy with standard cells increased
survival time from 6.7 to 11.3 h (Buffington et al.,
2009). Additionally, cells are being evaluated in an
ovine model of ESRD, where cell therapy is delivered
via peritoneal dialysis (Song et al., 2009). Results from
these lines of experimentation will be used to further
validate the use of IL8 secretion and gGT activity as
efficacy markers.
The EP method was developed to provide an adequate
and reliable supply of functional REC for integration into
a cell therapy device. While cryopreservation affected
the potential cell yield, only the very basic cryopreserva-
tion techniques were employed. Cell function and yield
are expected to improve with optimized cryopreservation
protocols. Cells derived from EP populations reconsti-
tuted post-cryopreservation were successfully integrated
into a renal cell therapy device and retained the correct
morphology through long-term in vitro maintenance in
a perfusion circuit and ex vivo extracorporeal haemodial-
ysis and peritoneal dialysis circuits. Application of the
EP protocol to human cadaver kidneys has greatly
enhanced cell proliferation, clearly demonstrating a ro-
bust cell source for renal cell therapy in two prospective
delivery systems.
Emphasis was not placed on understanding the mecha-
nisms responsible for the observed increase in yield.
More investigation into the factors influencing REC
amplification is merited and may provide further advance-
ment in renal cell progenitor technology, as well as
insight into progenitor amplification in other organ
systems.
4. Summary
As envisioned, application of the EP protocol to human
transplant discard kidneys increased cell yield dramatically
over the standard method for all six donors tested. The
generated cell number from each kidney was highly vari-
able and based on available information, correlated with
overall donor health. Yield exceeded 1016 cells/g cortex
from the only kidney obtained due to an anatomical de-
fect, while the average yield from diseased kidneys was
in the range 1.1109–8.81011 cells/g cortex, represent-
ing an increase of 10.31.4 doublings over standard
methods. Surrogate markers of efficacy, LPS-stimulated
IL8 secretion and gGTenzyme activity, were chosen because
they represent the ability to respond to endotoxin challenge
and oxidative stress. IL8 secretion and gGTactivity persisted
through advanced EP cultures. Stimulated IL8 secretion
was unaffected by cryopreservation, but gGT activity and
overall cell yield were significantly reduced. However, the
negative effects of cryopreservation may be resolved
with the application of more advanced cryopreservation
methods. Cells derived from EP populations reconstituted
post-cryopreservation were successfully integrated into a
renal cell therapy device and retained the correct morphol-
ogy through long-term in vitro maintenance in a perfusion
circuit and ex vivo extracorporeal haemodialysis and perito-
neal dialysis circuits. Application of the EP protocol to REC
expansion has solved the problem of cell sourcing as
the rate-limiting factor to the manufacture of cell-based
therapies targeting renal diseases, and may provide
a method for autologous device fabrication from core
kidney biopsies.
596 A. J. Westover et al.
Copyright © 2012 John Wiley & Sons, Ltd. J Tissue Eng Regen Med 2012;6: 589–597.
DOI: 10.1002/term
Acknowledgements
This work was made possible with NIH-NIDDK SBIR Grant
Nos 1R43DK082050-01, 1R43DK074289-01, 1R43DK074289-02,
1R43DK080529-03, 1R43DK080529-04 and DoD W81XWH-05-2-
01. We acknowledge the use of human tissues provided by the
National Disease Research Interchange (NDRI), with support from
NIH Grant No. 5 U42 RR006042-20.
Disclosure statement
H. D. Humes is a shareholder of Innovative BioTherapies
and CytoPherix Inc.
Supporting information on the
internet
The following supporting information may be found in
the online version of this article:
Video S1. Adherence and outgrowth of renal epithelial
progenitor cells, obtained using Zeiss AxioVision software
and 10 objective (1sec=40minutes).
Video S2. Doming behavior exhibited by differentiated
renal epithelial cells, obtained using Zeiss AxioVision
software and 10 objective (1sec=40minutes).
References
Al-Awqati Q, Oliver JA. 2006; The kidney
papilla is a stem cells niche. Stem Cell Rev
2(3): 181–184.
Bates DW, Su L, Yu DT, et al. 2001; Mortality
and costs of acute renal failure associated
with amphotericin B therapy. Clin Infect
Dis 32(5): 686–693.
Bi B, Schmitt R, Israilova M, et al. 2007; Stro-
mal cells protect against acute tubular
injury via an endocrine effect. J Am Soc
Nephrol 18(9): 2486–2496.
Bishop GA, Waugh JA, Hall BM. 1988;
Expression of HLA antigens on renal tubu-
lar cells in culture. Ii. Effect of increased
HLA antigen expression on tubular cell
stimulation of lymphocyte activation and
on their vulnerability to cell-mediated
lysis. Transplantation 46(2): 303–310.
Buffington DA, Hageman G, Lou L, et al.
2009; Design of a compact, cryoperserva-
ble, bioartificial renal cell system. J Am
Soc Nephrol 20: 27A.
Challen GA, Bertoncello I, Deane JA, et al.
2006; Kidney side population reveals mul-
tilineage potential and renal functional
capacity but also cellular heterogeneity. J
Am Soc Nephrol 17(7): 1896–1912.
Chertow GM, Levy EM, Hammermeister KE,
et al. 1998; Independent association
between acute renal and mortality follow-
ing cardiac surgery. Am J Med 104:
343–348.
Collins AJ, Kasiske B, Herzog C, et al. 2005;
Excerpts from the United States Renal
Data System 2004 Annual Data Report:
atlas of end-stage renal disease in the
United States. Am J Kidney Dis 45(1,
suppl 1): A5–7, S1–280.
Cukor D, Cohen SD, Peterson RA, et al.
2007; Psychosocial aspects of chronic dis-
ease: ESRD as a paradigmatic illness. J Am
Soc Nephrol 18(12): 3042–3055.
Duffield JS, Bonventre JV. 2005; Kidney
tubular epithelium is restored without
replacement with bone marrow-derived
cells during repair after ischemic injury.
Kidney Int 68(5): 1956–1961.
Gupta S, Verfaillie C, Chmielewski D, et al.
2002; A role for extrarenal cells in the re-
generation following acute renal failure.
Kidney Int 62(4): 1285–1290.
Hall PA, Watt FM. 1989; Stem cells): The
generation and maintenance of cellular
diversity. Development 106(4): 619–633.
Humes HD. 1995; Acute renal failure: pre-
vailing challenges and prospects for the
future. Kidney Int Suppl 50: S26–32.
Humes HD. 2000; Bioartificial kidney for full
renal replacement therapy. Semin Nephrol
20(1): 71–82.
Humes HD, Fissell WH, Weitzel WF. 2002;
The bioartificial kidney in the treatment
of acute renal failure. Kidney Int Suppl
80: 121–125.
Humes HD, Weitzel WF, Bartlett RH, et al.
2003; Renal cell therapy is associated with
dynamic and individualized responses in
patients with acute renal failure. Blood
Purif 21(1): 64–71.
Iglehart JK. 1993; The American health care
system. Teaching hospitals. N Engl J Med
329(14): 1052–1056.
Imai E, Iwatani H. 2007; The continuing
story of renal repair with stem cells. J Am
Soc Nephrol 18(9): 2423–2424.
Kale S, Karihaloo A, Clark PR, et al. 2003;
Bone marrow stem cells contribute to
repair of the ischemically injured renal
tubule. J Clin Invest 112(1): 42–49.
Krieg AF, Rosenblum LJ, Henry JB. 1967;
Lactate dehydrogenase isoenzymes a
comparison of pyruvate-to-lactate and
lactate-to-pyruvate assays. Clin Chem 13
(3): 196–203.
Leonard M, Ryan MP, Watson AJ, et al. 1999;
Role of map kinase pathways in mediating
IL-6 production in human primary mesan-
gial and proximal tubular cells. Kidney Int
56(4): 1366–1377.
Potten CS, Loeffler M. 1990; Stem cells: attri-
butes, cycles, spirals, pitfalls and uncer-
tainties. Lessons for and from the crypt.
Development 110: 1001–1020.
Poulsom R, Forbes SJ, Hodivala-Dilke K, et al.
2001; Bone marrow contributes to renal
parenchymal turnover and regeneration.
J Pathol 195(2): 229–235.
Prodjosudjadi W, Gerritsma JS, Klar-
Mohamad N, et al. 1995; Production and
cytokine-mediated regulation of monocyte
chemoattractant protein-1 by human prox-
imal tubular epithelial cells. Kidney Int 48
(5): 1477–1486.
Sagrinati C, Netti GS, Mazzinghi B, et al.
2006; Isolation and characterization of
multipotent progenitor cells from the Bow-
man’s capsule of adult human kidneys. J
Am Soc Nephrol 17(9): 2443–2456.
Saxen L. 1987; Organogenesis of the Kidney.
Cambridge University Press: New York.
Schrier RW, Wang W. 2004; Acute renal
failure and sepsis. N Engl J Med 351(2):
159–169.
Smith AM, Potter M, Merchant EB. 1967;
Antibody-forming cells in the pronephros of
the teleost Lepomis macrochirus. J Immunol
99(5): 876–882.
Smith PL, Buffington DA, Humes HD. 2006;
Kidney epithelial cells. Methods Enzymol
419: 194–207.
Song J, Jung J, Ding F, et al. 2009; Uremic
animal model of bioartificial renal cell
system (BRECS) using continuous flow
peritoneal dialysis-based extracorporeal
circuit. J Am Soc Nephrol 20: 106A.
Szasz G. 1974; Methods of Enzymatic Analy-
sis. Academic Press: New York.
Tumlin J, Wali R, Williams W, et al. 2008;
Efficacy and safety of renal tubule cell
therapy for acute renal failure. J Am Soc
Nephrol 19(5): 1034–1040.
Turpen JB, Knudson CM. 1982; Ontogeny of
hematopoietic cells in Rana pipiens: pre-
cursor cell migration during embryogene-
sis. Dev Biol 89(1): 138–151.
Van Den Hamer CJ, Elias RW. 1958; A
method for the determination of D()-
lactic acid. Biochim Biophys Acta 29(3):
556–562.
van Kooten C, van der Linde X, Woltman AM,
et al. 1999; Synergistic effect of interleu-
kin-1 and CD40l on the activation of hu-
man renal tubular epithelial cells. Kidney
Int 56(1): 41–51.
Wahl P, Schoop R, Bilic G, et al. 2002; Renal
tubular epithelial expression of the costi-
mulatory molecule b7rp-1 inducible costi-
mulator ligand. J Am Soc Nephrol 13(6):
1517–1526.
Wuthrich RP, Glimcher LH, Yui MA, et al.
1990; MHC class ii antigen presentation
and tumor necrosis factor in renal tubu-
lar epithelial cells. Kidney Int 37(2):
783–792.
Xue JI, Ma JZ, Louis TA, et al. 2001;
Forecast of the number of patients with
end-stage renal disease in the United
States to the year 2010. J Am Soc Nephrol
12: 2753–2758.
Zapata A. 1979; Ultrastructural study of the
teleost fish kidney. Dev Comp Immunol 3
(1): 55–65.
Adult renal progenitor cells for tissue therapy 597
Copyright © 2012 John Wiley & Sons, Ltd. J Tissue Eng Regen Med 2012;6: 589–597.
DOI: 10.1002/term
